证券之星消息，2月27日南向资金减持48.45万股阿里健康（00241.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持973.7万股。近20个交易日中，获南向资金增持的有14天，累计净增持3063.4 万股。截至目前，南向资金持有阿里健康（00241.HK）19.85亿股，占公司已发行普通股的12.26%。 阿里健康信息技术有限公司是一家为医疗医药行业提供产业互联网解决方案的投资控股公司，是阿里巴 巴控股在大健康领域的旗舰平台。该公司主要从事发展医药健康产品销售业务，营运医药电商平台及消 费医疗服务平台，通过云计算、大数据等技术发展追溯及数字医疗及互联网医疗业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

| 名称 | 现价 | 涨跌幅, | | --- | --- | --- | | 兆易创新 | 425.000 | 3.01% | | 澜起科技 | 195.000 | 1.51% | | 爱芯元智 | 28.680 | 1.34% | | 天数智芯 | 240.600 | 1.18% | | 中芯国际 | 70.650 | 1.15% | | 华虹未曾体 | 103.800 | 0.97% | | 壁仞科技 | 38.680 | 0.68% | | 英诺赛科 | 68.300 | 0.44% | 2月26日，香港恒生指数高开0.95%，恒生科技指数涨0.46%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | HSI | 恒生指数 | 27019.74 | 254.02 | 0.95% | | HSTECH 恒生科技 | | 5284.51 | 24.01 | 0.46% | | HSBIO | 恒生生物科技 | 15707.37 | 56.92 | 0.36% | | HSCEI | 恒生中国企业指数 | 9078.96 | 44 ...

阿里健康信息技术有限公司是一家为医疗医药行业提供产业互联网解决方案的投资控股公司，是阿里巴 巴控股在大健康领域的旗舰平台。该公司主要从事发展医药健康产品销售业务，营运医药电商平台及消 费医疗服务平台，通过云计算、大数据等技术发展追溯及数字医疗及互联网医疗业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月23日南向资金增持650.0万股阿里健康（00241.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持2014.2万股。近20个交易日中，获南向资金增持的有14天，累计净增持2054.1 万股。截至目前，南向资金持有阿里健康（00241.HK）19.85亿股，占公司已发行普通股的12.27%。 ...

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] Group 2 - The company maintains a "Buy" rating for Alibaba Health (00241) with a target price of HKD 7.8, expecting a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from FY2026 to FY2028, driven by growth in innovative drugs and healthcare products, deepening synergy with Alibaba Group (09988), and increasing AI application [1] - The company also favors Ping An Good Doctor (01833) with a "Buy" rating and a target price of HKD 20, anticipating a CAGR of 16% in revenue and 56% in adjusted net profit from FY2025 to FY2027, supported by deepening synergy with Ping An Insurance (02318) and ongoing AI empowerment [1] Group 3 - The company maintains an "Overweight" rating for the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - The company is optimistic about internet healthcare firms that effectively utilize real-world data to optimize AI algorithms and enhance service quality [2] - Preferred stocks include BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] - Alibaba Health (00241) is favored with a "Buy" rating and a target price of HKD 7.8, with expected revenue and adjusted net profit CAGR of 13% and 24% from FY2026 to FY2028, driven by innovative drugs, healthcare product growth, and deepening synergies with Alibaba [1] Group 2 - Ping An Good Doctor (01833) is also favored with a "Buy" rating and a target price of HKD 20, with expected revenue and adjusted net profit CAGR of 16% and 56% from FY2025 to FY2027, supported by synergies with Ping An (02318) and ongoing AI empowerment [1] - The firm maintains an "Overweight" rating on the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - Companies that effectively utilize real-world data to optimize AI algorithms and enhance service quality in internet healthcare are also favored, with preferred stocks including BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1: Industry Insights - The growth of online pharmaceutical sales is driven by the penetration of original research drugs and the outflow of prescriptions, with foreign companies increasing their presence in outpatient settings for innovative drugs [1] - Major pharmaceutical e-commerce and internet healthcare platforms are enhancing their product and service offerings around original research drugs, leading to a rapid increase in market share for medical e-commerce [1] - The long-term potential for online pharmacies is significant due to policy-driven factors such as online insurance and prescription outflow, highlighting the cost-effectiveness and convenience of online pharmacies [1] Group 2: Company Performance - Alibaba Health's self-operated revenue is accelerating, with self-operated business accounting for nearly 90% of total revenue, driven by the trend of original research drugs [2] - The number of self-operated SKUs increased by 99% year-on-year to 1.61 million, with revenue growing by 19% year-on-year to 14.38 billion yuan as of FY26H1 [2] - Alibaba Health is the largest online B2C healthcare retail platform in terms of annual GMV and has revised the upper limit of its advertising service framework agreement, which will significantly contribute to profitability [1][2] Group 3: Future Opportunities - The integration of AI in health management presents new opportunities for Alibaba Health, with the potential to enhance sales through the "Qianwen Super Agent" and related applications [2] - The company is exploring serious medical applications and has launched the medical AI assistant "Hydrogen Ion" App, which may lead to commercialization through partnerships with pharmaceutical companies [2] Group 4: Financial Projections - Revenue forecasts for Alibaba Health are projected at 34.594 billion yuan and 38.235 billion yuan for the fiscal years 26 and 27, respectively, with adjusted net profits expected to be 2.499 billion yuan and 3.026 billion yuan [2] - The pharmaceutical e-commerce business is assigned a 3X PS for FY26, while the healthcare and digital services business is assigned a 6X PS, leading to a target value of 7.39 HKD per share and a "Buy" rating [2]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Alibaba Health, indicating a reduction of 2.5 million shares on February 13, while there was a net increase of 28.064 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings on 8 occasions, resulting in a total net reduction of 62.917 million shares [1] - As of now, southbound funds hold 1.973 billion shares of Alibaba Health, which represents 12.19% of the company's total issued ordinary shares [1] Group 2 - Alibaba Health Information Technology Co., Ltd. is a holding company that provides industrial internet solutions for the medical and pharmaceutical industry, serving as Alibaba Group's flagship platform in the health sector [1] - The company primarily engages in the sales of pharmaceutical health products, operates an e-commerce platform for pharmaceuticals, and offers consumer healthcare services, leveraging technologies such as cloud computing and big data to develop traceability, digital healthcare, and internet medical services [1]

Investment Rating - The report assigns a "Buy" rating for Alibaba Health, with a target price of HKD 7.39 per share [7]. Core Insights - The main business of Alibaba Health is experiencing accelerated growth, driven by the online penetration of innovative drugs and the integration of AI technologies, which present new opportunities for the company [7]. - The self-operated revenue of Alibaba Health has significantly increased, accounting for nearly 90% of total revenue, with a year-on-year growth of 19% to RMB 14.38 billion [7]. - The company is also the largest online B2C healthcare product retail platform in China, benefiting from deep collaboration with the Alibaba Group [7]. Summary by Sections Medical E-commerce Tracking - The online pharmacy market share is rapidly increasing, with innovative drugs driving growth. The retail pharmacy share has risen to 31.5%, while online pharmacies have reached 5.3% [14][15]. - The demand for original research drugs is increasing, with a shift towards online channels due to convenience and service [15][16]. Alibaba Health - The self-operated business is the main driver of revenue growth, with a 99% year-on-year increase in self-operated SKUs to 1.61 million [7]. - The company is enhancing its advertising capabilities, which will contribute significantly to profitability [7]. - AI technologies are expected to empower the main business, with initiatives like the "Qianwen Super Agent" and the medical AI assistant "Hydrogen Ion" app being developed [7]. Profit Forecast and Valuation - Revenue forecasts for fiscal years 2026 and 2027 are RMB 34.594 billion and RMB 38.235 billion, respectively, with adjusted net profits of RMB 2.499 billion and RMB 3.026 billion [2][7].

Core Insights - Southbound funds increased their holdings in Alibaba Health (00241.HK) by 7.354 million shares on February 12 [1] - Over the past 5 trading days, there have been 5 days of net increases in holdings, totaling 34.802 million shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 133 million shares [1] - Currently, southbound funds hold 1.976 billion shares of Alibaba Health, representing 12.2% of the company's total issued ordinary shares [1] Company Overview - Alibaba Health Information Technology Co., Ltd. is an investment holding company providing industrial internet solutions for the medical and pharmaceutical industry [1] - The company primarily engages in the sales of pharmaceutical health products, operates a pharmaceutical e-commerce platform, and offers consumer healthcare services [1] - It leverages technologies such as cloud computing and big data to develop traceability, digital healthcare, and internet medical services [1]

Group 1 - The APEC 33rd Leaders' Informal Meeting will be held in Shenzhen in November 2026, with the city aiming to enhance its internationalization and openness levels [1] - Shenzhen's government report emphasizes the need for a professional, safe, and fruitful high-level event, showcasing a friendly and inclusive cultural image [1] - Local representatives are actively proposing ideas to leverage the historical opportunity presented by the APEC meeting [1] Group 2 - A suggestion was made to improve the international language environment in Shenzhen by implementing multilingual signage and training for service personnel [2] - The establishment of a multilingual service coordination center is proposed to enhance language service capabilities [2] - Continuous feedback collection from international residents is recommended to improve the language service environment [2] Group 3 - A "one-stop" service platform for international talent is proposed to enhance the digital experience and support for foreign personnel [3] - The integration of design and technology in public facilities around the APEC venue is suggested to reflect Shenzhen's identity as a "Design City" and "Innovation Center" [3] - Strengthening cross-border financial and commercial dispute resolution services is recommended to deepen regional cooperation [3] Group 4 - Shenzhen's 14th Five-Year Plan aims to develop a globally influential consumption center, leveraging the APEC meeting for international cooperation [4] - The healthcare sector is encouraged to integrate with international service capabilities, creating a brand for "APEC Shenzhen Health Tour" [4] - The promotion of Shenzhen's technological innovations and products on a global stage is emphasized to enhance the city's commercial ecosystem [4]